Is 2197.HK overvalued or undervalued?

2197.HK currently has a P/E ratio of 2.31. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Clover Biopharmaceuticals, Ltd. stock?

Clover Biopharmaceuticals, Ltd. trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 2197.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 2197.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 2197.HK to protect their purchasing power. Because 2197.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 2197.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 2197.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 2197.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks2197.HK

Clover Biopharmaceuticals, Ltd.

HK$1.79-HK$0.01-0.28%

HKSE / HKD

Market cap

HK$2.3B

P/E

2.3

EPS (TTM)

HK$0.10

Dividend yield

0.00%

Beta

2.58

1Y return

-28.97%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$02021

$02022

$6M2023

$5M2024

$488,1062025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity-0.00Low
Current ratio0.73
Cash ratio0.50
Net margin199,197.3%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

2197.HK2.3
Healthcare sector median26.8
S&P 50022.0

Trades about 91% below its sector, cheaper than its peers on earnings.

Ratios

PEG0.00
Price to book-2.41
EPS (TTM)HK$0.10
Payout ratio0%
FCF yield-7.19%

Range & risk

HK$1.32HK$3.20

Trading in the lower third of its 52-week band

Beta2.58

Profile

What Clover Biopharmaceuticals, Ltd. actually does

Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.

CEO

Joshua G. Liang

Employees

257

Headquarters

Shanghai, SH

Founded

2021-11-05

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 2197.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

2197.HK has a beta of 2.58, which indicates how sensitive it has historically been to movements in its broader market. A beta above 1 suggests higher relative volatility than the market. Beta is based on historical data and does not predict future performance.

Clover Biopharmaceuticals, Ltd.